Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium Carbonate in Early Thyroid Cancer Ablation
NCT00251316Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Nov 2005
- Primary completion
- Dec 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) comparing Lithium Carbonate with Placebo (2 arms). Primary endpoint: The Rate of Successful Thyroid Ablation as Defined by Negative Recombinant Human Thyrotropin (rhTSH) Stimulated Radioiodine Whole Body Scan (RAI WBS) at 1 Year. Started Nov 2005; status: completed.
02
Drugs
lithium carbonate
03
Conditions
papillary thyroid cancer (PTC)follicular thyroid cancer (FTC)
Beyond the preview
Go deeper on NCT00251316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251316.